Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid ...( BOSTON Oct. 5 /- Surface Logix In...),Health

BOSTON, Oct. 5 /PRNewswire/ -- Surface Logix, Inc. today announced the presentation of positive safety and efficacy data from its innovative Phase 1 repeat-dose clinical trial of its investigational drug candidate SLx-4090, a first-in-class enterocyte-specific microsomal triglyceride transfer protein (MTP) inhibitor being developed for the treatment of dyslipidemia (abnormal levels of lipids in the bloodstream). The data indicated not only that repeat- dosing at all dose levels of SLx-4090 was well tolerated, with no serious adverse events reported, but also that SLx-4090 significantly decreased plasma levels of both triglyceride and LDL-cholesterol compared to placebo. These data extend earlier findings previously reported from a single-dose study relating to the safety, tolerability and pharmacokinetic and pharmacodynamic profiles of SLx-4090. Results were presented at the 16th International Symposium on Drugs Affecting Lipid Metabolism being held October 4-7 in New York, NY.

"It is exciting that this novel compound continued to perform so well in this first repeat-dose study," said Dr. William Prince, Chief Development Officer of Surface Logix. "Consistent with our preclinical and Phase 1 single-dose results, no drug was detected in the plasma at doses up to 200 mg given three times daily for two weeks. This is particularly notable, as all other known MTP inhibitors have been shown to enter the systemic circulation and negatively impact standard measures of liver function. SLx-4090 was extremely well tolerated and adverse events were similar to those seen with placebo."

"Based on the results of this study, we have advanced SLx-4090 into a Phase 2a study, which will be completed shortly, and initial results are confirming the profile seen in both Phase 1 studies," said Jim Mahoney, President and Chief Executive Officer of Surface Logix. "We are also planning to start a Phase 2b study in patients with dyslipidemia in the middle of 2008. Based on
'/>"/>